Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

Autores: Kaufman, J. L.; Dimopoulos, M. A. ; Leiba, M.; Morton, J.; Ho, P. J. ; Kim, K.; Moreau, P. ; Sutherland, H. J.; Iida, S.; Kim, J. S.; Prince, H. M.; Rocafiguera, A. O.; Bahlis, N. J.; Chari, A. ; Avet-Loiseau, H. ; Chiu, C. ; Soong, D. ; Ukropec, J.; Qi, M.; San Miguel Izquierdo, Jesús